LLY 10-Q Quarterly Reports

Eli Lilly and Company (LLY) reported a robust third quarter of 2025, showcasing significant growth across key financial metrics. Revenue for the quarter surged by 54% year-over-year to $17.6 billion, driven by strong volume increases from Mounjaro and Zepbound, which experienced substantial growth both in the U.S. and internationally. This top-line performance translated into impressive profitability, with net income soaring by over 470% to $5.6 billion, and diluted earnings per share reaching $6.21, up from $1.07 in the prior year period. The company's gross margin improved to 82.9%, reflecting favorable product mix and cost efficiencies. Looking at the nine-month period, the positive trends continued, with revenue up 46% to $45.9 billion and net income more than doubling to $14.0 billion. These strong results highlight the company's successful execution in bringing novel therapies to market and expanding their reach. Lilly's ongoing investment in research and development remains substantial, underscoring its commitment to future innovation, while marketing and administrative expenses also increased to support commercial launches. The balance sheet remains strong, with a significant increase in cash and cash equivalents, providing flexibility for continued investment and strategic initiatives.

Eli Lilly and Company (LLY) reported robust financial performance for the quarter and six months ended June 30, 2025. Revenue surged by 38% and 41% year-over-year, respectively, driven by strong demand for key products like Mounjaro and Zepbound, particularly in the U.S. market. This top-line growth translated into a significant increase in net income, up 91% for the quarter and 62% for the six-month period, with diluted EPS also showing substantial gains. The company's gross margin improved due to better production costs and product mix, even with increased R&D and SG&A expenses supporting pipeline development and commercialization efforts. Despite increased investments in research and development and marketing, Lilly demonstrated strong operational efficiency. The company also made strategic acquisitions, including Verve Therapeutics and SiteOne Therapeutics, to bolster its pipeline in cardiovascular disease and pain management, respectively. Financially, Lilly maintained a healthy cash position, though total debt increased due to recent debt issuances primarily to fund acquisitions and general business purposes. The company also continued its share repurchase program and dividend payments, reflecting a commitment to shareholder returns.

Eli Lilly and Company (LLY) reported a strong first quarter for 2025, with revenue soaring by 45% year-over-year to $12.7 billion, driven by significant growth in key products like Mounjaro and Zepbound. Net income also saw a substantial increase of 23%, reaching $2.76 billion. This impressive performance reflects robust demand and improved gross margins, although offset by higher acquired in-process R&D charges and increased marketing expenses. The company's strategic focus on innovation and pipeline development continues, as evidenced by a significant increase in acquired in-process R&D, primarily related to the Scorpion Therapeutics acquisition. While R&D expenses saw a moderate increase, the company's commitment to developing new medicines remains a core driver of its long-term strategy. Lilly's financial position remains solid, with ample liquidity and cash flow to support its operations, ongoing investments in manufacturing capacity, and shareholder returns through its share repurchase program and dividends.

Eli Lilly and Company reported strong financial results for the third quarter and the first nine months of 2024, with significant revenue growth driven by key products like Mounjaro®, Zepbound®, and Verzenio®. Revenue for the quarter reached $11.4 billion, a 20% increase year-over-year, and $31.5 billion for the first nine months, up 27%. This growth was primarily fueled by strong volume increases in the U.S. for Mounjaro and Zepbound, alongside Verzenio's continued expansion. While the company experienced a net loss of $57.4 million in Q3 2023, it achieved a net income of $970.3 million in Q3 2024, and year-to-date net income more than doubled to $6.18 billion. The company's pipeline remains robust, with several new molecular entities (NMEs) and line extensions in late-stage clinical trials across key therapeutic areas. Management highlighted ongoing investments in manufacturing capacity to meet demand, particularly for tirzepatide (Mounjaro/Zepbound). Despite facing pressures from healthcare legislation like the Inflation Reduction Act (IRA) and ongoing litigation, Lilly's financial performance and strategic investments position it for continued growth.

Eli Lilly and Company (LLY) reported strong financial results for the second quarter and first half of 2024, showcasing significant revenue and net income growth. Revenue surged by 36% year-over-year for the quarter and 31% for the first half, driven by robust sales of key products like Mounjaro®, Zepbound®, and Verzenio®. This growth was further bolstered by increased volume and higher realized prices, particularly in the U.S. market, and improved channel dynamics for their incretin medicines. Profitability also saw substantial improvement, with diluted earnings per share rising by 68% for both the quarter and the first half. This strong performance was supported by an improved gross margin, reflecting favorable pricing and product mix. While research and development and marketing, selling, and administrative expenses increased to support pipeline development and launches, the company maintained a healthy increase in net income. Eli Lilly also announced a proposed acquisition of Morphic Holding, Inc. for approximately $3.2 billion, indicating continued strategic investment in its pipeline. The company continues to invest heavily in expanding manufacturing capacity, particularly for its incretin medicines, though periodic supply tightness is still a consideration. The pipeline remains robust with numerous new medicine candidates in late-stage development across key therapeutic areas, including cardiometabolic health, immunology, neuroscience, and oncology. These developments, combined with strong financial performance, position Eli Lilly for continued growth.

Eli Lilly and Company (LLY) reported robust financial results for the first quarter of 2024, with total revenue reaching $8.77 billion, a significant 26% increase year-over-year. This growth was largely driven by strong performance in key products like Mounjaro, Zepbound, Verzenio, and Jardiance, despite supply constraints for some incretin medicines. Net income surged by 67% to $2.24 billion, translating to diluted earnings per share of $2.48, a 66% increase from the prior year's first quarter. The company continues to invest heavily in research and development, with R&D expenses increasing by 27% to $2.52 billion, reflecting its commitment to pipeline expansion. Marketing, selling, and administrative expenses also saw an increase of 12%. Despite increased operational costs, Eli Lilly demonstrated improved profitability, with gross margin as a percentage of revenue rising to 80.9%, up from 76.6% in the prior year's comparable quarter, attributed to favorable pricing and product mix. The company's financial position remains strong, with sufficient liquidity to fund operations and planned capital expenditures.

Eli Lilly and Company (LLY) reported a significant increase in revenue for the third quarter of 2023, driven by strong sales of key products like Mounjaro® and Verzenio®, alongside revenue from the divestiture of the olanzapine portfolio. Despite the revenue growth, the company reported a net loss for the quarter, primarily due to substantial acquired in-process research and development (IPR&D) charges related to recent acquisitions, as well as increased research and development and marketing expenses. For the nine-month period ending September 30, 2023, revenue also saw a healthy increase, though net income and diluted EPS declined year-over-year. This decline is largely attributed to the same factors impacting the quarterly results: significant IPR&D expenses and higher operating costs, partially offset by robust top-line growth. The company continues to invest heavily in its late-stage pipeline, with numerous promising candidates in development across various therapeutic areas, including diabetes, obesity, immunology, neuroscience, and oncology.

Eli Lilly and Company reported robust financial results for the second quarter and first half of 2023, demonstrating significant revenue and net income growth. Total revenue increased by 28% in the second quarter and 7% year-to-date, driven by strong volume increases in key products like Mounjaro, Verzenio, Jardiance, and Taltz, along with a notable contribution from the sale of Baqsimi rights. Net income saw a substantial rise of 85% in the quarter and 9% year-to-date, attributed to higher revenues, reduced acquired in-process R&D charges, and strategic pipeline investments. The company continues to invest heavily in research and development, with expenses increasing by 32% and 28% for the respective periods, reflecting a strong commitment to its late-stage pipeline, including promising treatments for diabetes, obesity, immunology, and neuroscience. Acquisitions, such as the announced deal for DICE Therapeutics, underscore Lilly's strategy to expand its portfolio and therapeutic reach. Despite supply chain challenges for incretin products like Mounjaro and Trulicity, the company is actively expanding manufacturing capacity to meet demand. Looking ahead, Lilly faces potential headwinds from evolving pharmaceutical pricing regulations, including the Inflation Reduction Act, but remains focused on innovation and growth.

Eli Lilly and Company reported a decrease in revenue for the first quarter of 2023, down 11% year-over-year to $7.0 billion, primarily due to the cessation of COVID-19 antibody sales and lower realized prices. Net income also saw a significant decline of 29% to $1.34 billion, or $1.49 per diluted share. This downturn was partially offset by strong growth in key products like Mounjaro and Verzenio, and a notable improvement in gross margin percentage, driven by the shift away from lower-margin COVID-19 antibody sales. Despite the top-line decrease, the company continues to invest heavily in research and development, with expenses up 23% driven by late-stage asset development. The company also announced significant divestiture agreements for the olanzapine portfolio (Zyprexa) and Baqsimi, which are expected to close in April 2023, generating substantial cash proceeds. Eli Lilly's financial position remains robust, with an increase in cash and cash equivalents and continued share repurchases, indicating confidence in future growth prospects, particularly from its innovative pipeline.

Eli Lilly and Company (LLY) reported a solid third quarter of 2022, with revenue reaching $6.94 billion, a 2% increase year-over-year, driven by strong volume growth across key products, especially in the U.S. Diluted Earnings Per Share (EPS) also saw a significant increase of 32% to $1.61. The company's product portfolio continues to perform well, with notable growth in Trulicity, Verzenio, and Jardiance. While the company is investing heavily in research and development ($1.8 billion for the quarter) and faced some headwinds from foreign exchange rates and the phasing out of COVID-19 antibody sales, its overall financial health remains robust, supported by substantial operating cash flow and a strong balance sheet.

Eli Lilly and Company (LLY) reported its financial results for the second quarter and first half of 2022. For the three months ended June 30, 2022, revenue was $6.49 billion, a decrease of 4% compared to the prior year, impacted by lower realized prices and foreign exchange rates, though partially offset by increased volume. Net income for the quarter was $952.5 million, or $1.05 per diluted share, a decrease from $1.39 billion ($1.53 per diluted share) in the same period last year. For the first six months of 2022, revenue increased by 6% to $14.30 billion, while net income saw a modest increase of 4% to $2.86 billion, or $3.16 per diluted share. The company's performance was influenced by several factors, including strong volume growth in key products like Trulicity, Taltz, and Verzenio, which helped drive the year-to-date revenue increase. However, the decline in revenue for the quarter was significantly impacted by the substantial decrease in sales of COVID-19 antibodies and the ongoing generic competition for Alimta. Research and development expenses saw an increase, reflecting continued investment in late-stage assets. The company also noted substantial charges related to acquired in-process R&D and development milestones, primarily associated with a buy-out of future obligations for a PI3Kα inhibitor.

Eli Lilly and Company reported robust revenue growth of 15% year-over-year for the first quarter of 2022, reaching $7.81 billion. This increase was primarily driven by strong volume growth, particularly from key products like Trulicity, Verzenio, and Jardiance, as well as significant contributions from COVID-19 antibody treatments. Despite the strong top-line performance, the company's net income saw a substantial increase of 40% to $1.9 billion, translating to a diluted EPS of $2.10, up from $1.49 in the prior year period. The company's operational expenses showed a mixed trend. Research and development expenses saw a slight decrease, attributed to lower spending on COVID-19 antibody development, while marketing, selling, and administrative costs remained relatively flat. A notable item was the reduction in acquired in-process R&D expenses. The company also repurchased $1.5 billion in shares during the quarter, signaling a continued commitment to returning capital to shareholders. Eli Lilly maintains a strong financial position with ample liquidity to fund its operations and pipeline development.

Eli Lilly and Company (LLY) reported a strong increase in revenue for the nine months ended September 30, 2021, up 19% year-over-year to $20.3 billion, driven by higher volumes across key products and contributions from COVID-19 therapies. Despite revenue growth, net income and diluted EPS saw a decline of 5% and 5% respectively, primarily due to increased operating expenses, particularly in research and development for late-stage assets, and a significant debt extinguishment loss of $405.2 million. The company also incurred a substantial $435.1 million net inventory impairment charge for its COVID-19 antibodies due to changing demand and near-term expiry dates. Management has updated its full-year 2021 financial guidance, anticipating revenue between $27.2 billion and $27.6 billion, and EPS between $6.38 and $6.48, reflecting improved COVID-19 antibody revenue projections. Key product highlights include robust growth for Trulicity (up 29% YTD) and Taltz (up 21% YTD), while Alimta faces significant revenue erosion due to generic competition following patent expiries. The company continues to invest heavily in its late-stage pipeline, with approximately 45 candidates in clinical development, including promising advancements in areas like Alzheimer's disease (Donanemab) and Type 2 diabetes (Tirzepatide). The company's financial position remains solid, with cash and cash equivalents increasing and substantial unused credit facilities available.

Eli Lilly and Company reported strong revenue growth of 23% for the three months ended June 30, 2021, reaching $6.74 billion, and a 19% increase for the six months ended June 30, 2021, totaling $13.55 billion, compared to the prior year periods. This growth was driven by increased volume across key products like Trulicity, Taltz, and Verzenio, as well as favorable foreign exchange rates. While gross margin percentage saw a dip due to significant inventory charges related to COVID-19 antibodies, the company maintained profitability, with net income for the quarter at $1.39 billion, though slightly down year-over-year. The company also announced updated full-year 2021 financial guidance, anticipating revenue between $26.8 billion and $27.4 billion and earnings per share between $6.73 and $6.93.

Eli Lilly and Company reported robust revenue growth of 16% for the first quarter of 2021, reaching $6.81 billion, up from $5.86 billion in the prior year period. This increase was primarily driven by higher sales volumes, particularly from its COVID-19 antibody treatments and key growth products like Trulicity and Verzenio. Despite the strong top-line performance, net income saw a decline of 7% to $1.36 billion, translating to diluted EPS of $1.49, down from $1.60 in Q1 2020. This decrease in profitability is largely attributable to significant increases in research and development expenses, higher acquired in-process R&D charges related to strategic acquisitions, and increased asset impairment and restructuring costs. The company's strategic acquisitions of Prevail Therapeutics and Dermira are beginning to impact the financial statements, with substantial acquired in-process R&D recognized in the current quarter. While the company is managing its liquidity effectively, with cash and cash equivalents at $3.00 billion, investors should note the impact of increased R&D spending on future growth and the ongoing challenges related to patent expirations for key products like Alimta.

Eli Lilly and Company (LLY) reported a 5% increase in revenue for the third quarter of 2020, reaching $5.74 billion, and a 6% increase year-to-date to $17.10 billion. This growth was primarily driven by increased product volume across key therapeutic areas, including diabetes and immunology, despite some pricing pressures. Net income for the quarter slightly decreased by 4% to $1.21 billion, translating to diluted EPS of $1.33, compared to $1.37 in the prior year. However, year-to-date net income saw a substantial 30% increase to $4.08 billion, excluding the impact of discontinued operations and a significant gain from the Elanco disposition in the prior year. The company continued to invest heavily in research and development, with a focus on COVID-19 treatments and its robust late-stage pipeline. Acquisitions in 2020, such as Dermira, strengthened the company's portfolio. Lilly's financial position remains strong, with increased cash and cash equivalents and access to credit facilities, enabling continued operations and strategic investments. The company reaffirmed its full-year 2020 revenue guidance and updated its EPS guidance.

Eli Lilly and Company's (LLY) second-quarter 2020 results show resilience despite the ongoing COVID-19 pandemic, which caused an estimated $250 million revenue impact due to delayed prescription trends and decreased customer buying. Revenue for the quarter was $5.50 billion, a slight decrease of 2% compared to the prior year, while the six-month period saw a 6% increase to $11.36 billion. Net income from continuing operations for the quarter rose by 6% to $1.41 billion, or $1.55 per diluted share, indicating strong operational performance. The company continues to invest heavily in its late-stage pipeline, with key developments like the U.S. approval and launch of Retevmo (selpercatinib) for certain cancers and progress in trials for treatments like tirzepatide for type 2 diabetes. Despite revenue headwinds from COVID-19, Lilly demonstrated effective cost management, with operating expenses decreasing by 5% for the quarter. The company's financial position remains robust, supported by $2.37 billion in cash and cash equivalents. Management is updating its full-year 2020 EPS guidance to a range of $6.48 to $6.68, while maintaining its revenue expectation of $23.7 billion to $24.2 billion. Key growth drivers are expected to include Trulicity, Taltz, Jardiance, and Verzenio, though patent expirations for products like Forteo and potential generic competition for others like Alimta and Humalog present ongoing challenges.

Eli Lilly and Company reported a significant increase in revenue for the first quarter of 2020, reaching $5,859.8 million, up 15% from $5,092.2 million in the prior year period. This growth was primarily driven by increased sales volumes across key products, including Trulicity, Taltz, and Jardiance, partially offset by lower realized prices. The company also noted a favorable impact of approximately $250 million on revenue due to increased customer buying patterns and prescription trends related to the COVID-19 pandemic, particularly in the diabetes and immunology segments. Net income from continuing operations saw a substantial rise to $1,456.5 million ($1.60 per diluted share) from $561.1 million ($0.57 per diluted share) in Q1 2019. However, reported net income for Q1 2020 was $1,456.5 million, a decrease from $4,241.6 million in Q1 2019, primarily due to a significant gain on the disposition of Elanco Animal Health recognized in the prior year. The company continued its strategic investments, completing the acquisition of Dermira, Inc. in February 2020, which added new assets like lebrikizumab to its pipeline. Management highlighted ongoing R&D efforts and provided financial expectations for the full year 2020, anticipating EPS in the range of $6.20 to $6.40.

Eli Lilly and Company (LLY) reported strong financial performance for the third quarter and first nine months of 2019. Revenue saw a modest increase of 3% for the quarter and 2% for the nine-month period, reaching $5.48 billion and $16.21 billion, respectively. Net income from continuing operations grew significantly by 15% for the quarter and 55% for the nine months, primarily driven by a substantial gain from the disposition of Elanco Animal Health, which significantly boosted overall net income to $1.25 billion for the quarter and $6.82 billion for the nine months. Earnings per share also reflected this growth, with diluted EPS from continuing operations at $1.37 for the quarter and $3.33 for the nine months. Key strategic moves during the period included the acquisition of Loxo Oncology for $6.92 billion, aimed at bolstering the company's pipeline in oncology. The company continued to experience robust growth in key products such as Trulicity, Taltz, Basaglar, Jardiance, and Verzenio, which offset declines in legacy products like Cialis due to patent expirations. Despite ongoing patent challenges, particularly for Alimta, and increased pricing pressures in the U.S. pharmaceutical market, Lilly maintained its financial momentum.

Eli Lilly and Company (LLY) reported solid financial results for the quarter and six months ended June 30, 2019. Revenue saw a modest increase year-over-year, driven by volume growth, though partially offset by pricing pressures and foreign exchange rates. A significant highlight was the substantial gain recognized from the disposition of Elanco Animal Health, which significantly boosted net income and earnings per share for the six-month period. The company continued to invest in its robust R&D pipeline, with increased expenses reflecting development for late-stage assets and recently launched products. Looking ahead, Lilly reaffirmed its full-year 2019 financial expectations, anticipating revenue between $22.0 billion and $22.5 billion and EPS in the range of $8.58 to $8.68. The company remains focused on driving growth through key products like Trulicity, Taltz, Jardiance, and Basaglar, while managing the impact of patent expirations on older products and navigating a complex regulatory and pricing environment, particularly in the U.S. The acquisition of Loxo Oncology in February 2019 represents a strategic investment to strengthen its pipeline with promising investigational medicines.

Eli Lilly and Company reported strong revenue growth in the first quarter of 2019, with a total of $5.1 billion, a 3% increase year-over-year. This growth was primarily driven by increased volume across key products like Trulicity, Taltz, and Basaglar, offsetting some pricing pressures. The company also completed the significant disposition of its remaining stake in Elanco Animal Health, recognizing a substantial gain and impacting net income positively. Despite revenue growth, net income from continuing operations saw a significant decrease of 52% to $561.1 million. This was largely due to increased investments in research and development and marketing, as well as substantial charges related to the acquisition of Loxo Oncology. The acquisition of Loxo, valued at $6.92 billion, is expected to bolster Lilly's oncology pipeline with promising investigational medicines. Investors should monitor the impact of patent expirations on key products like Alimta and Forteo, as well as ongoing legal and regulatory matters, which could affect future financial performance.

Eli Lilly and Company reported a solid third quarter of 2018, with revenue increasing by 7% year-over-year to $6,061.9 million, driven primarily by volume growth in key pharmaceutical products. Diluted Earnings Per Share (EPS) also saw a significant increase, more than doubling to $1.12 compared to $0.53 in the prior year period. This performance was supported by strong demand for newer products like Trulicity, Taltz, and Basaglar, alongside continued contributions from established products. The company also made significant strategic moves during the quarter, including the initial public offering (IPO) of its Elanco Animal Health business, which is expected to drive future shareholder value. While facing ongoing challenges from patent expirations and generic competition for some older products, Lilly's robust pipeline and focus on innovative therapies appear to be yielding positive results, as reflected in the overall financial growth. Management expressed confidence in the company's ability to fund ongoing operations, dividends, and share repurchases through operational cash flow.

Eli Lilly and Company reported a significant increase in revenue for the second quarter and the first six months of 2018 compared to the prior year, driven by strong volume and favorable foreign exchange rates. However, the company posted a net loss of $259.9 million for the quarter, a stark contrast to the $1.008 billion net income in the same period last year. This loss was heavily influenced by a substantial $1.62 billion charge related to acquired in-process research and development (IPR&D) for acquisitions like ARMO Biosciences and AurKa Pharma, as well as a collaboration with Sigilon Therapeutics. Despite the quarterly loss, the first six months of the year remained profitable with $957.5 million in net income. Key developments include significant investments in late-stage pipeline assets and ongoing strategic review of the Elanco animal health business, with plans for a potential IPO. The company also faces ongoing patent litigation, particularly concerning Alimta, which could materially impact future results. Investors should note the substantial R&D investment and the impact of acquisitions on the current quarter's profitability, while revenue growth trends remain positive.

Eli Lilly and Company reported strong financial performance for the first quarter of 2018, with a significant turnaround from the prior year. Revenue increased by 9% year-over-year to $5.7 billion, driven by favorable foreign exchange rates, higher realized prices, and increased product volumes. This revenue growth, coupled with a reduction in operating expenses (down 5%), led to a substantial net income of $1.2 billion, a significant improvement from a net loss of $110.8 million in the first quarter of 2017. The company also benefited from lower asset impairment, restructuring, and special charges compared to the previous year, and the absence of a large acquired in-process R&D charge that impacted 2017 results. The company is actively managing its late-stage pipeline, with several new molecular entities (NMEs) in various stages of development and regulatory review, including treatments for migraine, Alzheimer's disease, and diabetes. However, the company faces ongoing challenges related to patent expirations for key products like Cialis and Alimta, which are expected to lead to a decline in revenue due to generic competition. Eli Lilly is also exploring strategic alternatives for its Elanco Animal Health business.

Eli Lilly and Company (LLY) reported a mixed financial performance for the third quarter and the first nine months of 2017. Revenue saw a notable increase of 9% year-over-year for the quarter, reaching $5.66 billion, and an 8% increase for the nine-month period to $16.71 billion. This growth was primarily driven by strong volume increases in key new pharmaceutical products like Trulicity, Taltz, and Basaglar. However, net income declined significantly, by 29% for the quarter to $555.6 million and by 26% for the nine months to $1.45 billion. This decline was largely attributable to substantial charges related to acquired in-process research and development (IPR&D) and asset impairment, restructuring, and other special charges, which notably increased in 2017 compared to the prior year. These charges, particularly the non-tax deductible IPR&D acquisition of CoLucid, significantly impacted profitability. Despite the decrease in net income, the company's financial condition remains solid. Cash and cash equivalents stood at $3.72 billion at the end of September 2017, though this was a decrease from year-end 2016, likely due to significant investments in acquisitions and debt management. Total debt increased due to new note issuances. Management expects full-year 2017 EPS to be between $1.73 and $1.83, reflecting the impact of these charges. Investors should monitor the ongoing patent challenges for key products like Alimta and Effient, as well as upcoming patent expirations for Cialis, which could materially affect future revenue.

Eli Lilly and Company reported solid revenue growth for the first six months of 2017, up 8% year-over-year to $11.05 billion. This growth was primarily driven by increased sales volume for key products like Trulicity and Taltz, along with contributions from recent acquisitions. However, net income for the six-month period saw a significant decline of 24% to $897.2 million. This decrease was largely due to a substantial $857.6 million acquired in-process research and development (IPR&D) charge related to the acquisition of CoLucid Pharmaceuticals, Inc. in March 2017, which was non-tax deductible. Despite the bottom-line dip, the company's financial health remains robust, with a healthy gross margin of 73.9% for the period. Lilly also continues to invest heavily in its pipeline, with numerous new molecular entities (NMEs) in late-stage clinical trials. However, investors should note the significant patent expirations on the horizon for key products like Cialis, Strattera, and Alimta, which are expected to materially impact future revenues and earnings. The company provided an updated full-year 2017 EPS guidance of $2.51 to $2.61 and revenue guidance of $22.0 billion to $22.5 billion.

Eli Lilly and Company (LLY) reported a net loss of $110.8 million for the first quarter of 2017, a significant shift from the $440.1 million net income in the same period of the prior year. This loss was primarily driven by a substantial $857.6 million charge for acquired in-process research and development (IPR&D) related to the acquisition of CoLucid Pharmaceuticals, which is not tax-deductible and heavily impacted profitability. Despite the net loss, total revenue saw a healthy increase of 7% to $5.23 billion, supported by strong volume growth in key products like Trulicity and Taltz, as well as the inclusion of revenues from the Boehringer Ingelheim Vetmedica acquisition. Investors should note the ongoing patent challenges for key products like Alimta, which, coupled with upcoming patent expirations for other significant products such as Strattera, Cialis, and Effient, present considerable future revenue risks. The company also saw increased operating expenses, with a 5% rise in marketing, selling, and administrative expenses, partly due to investments in new pharmaceutical products. While the company reaffirms its full-year revenue guidance, the EPS outlook has been revised downwards due to the IPR&D charge and restructuring costs.

Eli Lilly and Company's (LLY) third quarter 2016 report shows a 5% increase in revenue to $5.19 billion, driven by strong performance in the U.S. and growth in key products like Trulicity and Erbitux. Despite the revenue growth, net income saw a slight decrease of 3% to $778 million, primarily due to higher operating expenses, particularly in research and development, and a significant charge related to the Venezuelan financial crisis. Looking ahead, the company faces ongoing challenges related to patent expirations for key products such as Alimta, Cymbalta, Strattera, Effient, and Cialis, which are expected to materially impact future revenues. However, Lilly is actively managing its product portfolio, with new approvals like Taltz and Portrazza, and a robust pipeline including Baricitinib and Abemaciclib, aiming to mitigate these risks and drive future growth.

Eli Lilly and Company reported strong revenue growth of 9% for the quarter ended June 30, 2016, reaching $5.4 billion, and 7% for the six-month period, totaling $10.3 billion. This growth was primarily driven by increased volume in key products such as Trulicity®, Erbitux®, and Humalog®, as well as strong performance in the U.S. market. Net income saw a significant increase of 24% for the quarter to $747.7 million, and a 5% increase for the six-month period to $1.19 billion. Earnings per share (EPS) also demonstrated positive momentum, up 27% for the quarter and 6% for the six-month period, benefiting from a higher gross margin and a reduction in prior-year charges like acquired in-process R&D and debt repurchase expenses. Despite the positive financial performance, investors should note potential headwinds. The company faces ongoing patent expirations and the increasing threat of generic competition for key products like Alimta®, Zyprexa®, Strattera®, and Cialis®, which are expected to materially impact future revenues. Additionally, a significant charge related to the Venezuelan financial crisis and ongoing legal and patent litigations for products like Alimta and Effient present continued risks. Management reaffirmed its full-year 2016 financial guidance, expecting EPS between $2.68 and $2.78 and revenue between $20.6 billion and $21.1 billion, indicating confidence in continued performance.

Eli Lilly and Company (LLY) reported Q1 2016 revenue of $4.87 billion, a 5% increase year-over-year, primarily driven by volume growth in the U.S. and internationally. Despite revenue growth, net income decreased by 17% to $440.1 million ($0.41 diluted EPS) compared to $529.5 million ($0.50 diluted EPS) in Q1 2015. This decline was significantly impacted by a $203.9 million charge related to the Venezuelan financial crisis and deterioration of the bolívar, along with higher research and development expenses and asset impairment charges. Key product drivers included strong performance from Trulicity and Erbitux (especially in the U.S. post-acquisition of commercialization rights), along with established products like Cialis and Humulin showing growth. However, the company faces significant headwinds from upcoming patent expirations for major drugs such as Alimta, Strattera, and Cialis, which are expected to lead to substantial revenue declines. Lilly is actively managing its pipeline with several new molecular entities (NMEs) in late-stage development, including baricitinib for rheumatoid arthritis which was submitted for regulatory review.

Eli Lilly and Company's (LLY) Q3 2015 report shows a modest revenue increase year-over-year, driven by growth in the U.S. market, partially offset by unfavorable foreign exchange rates impacting international sales. The company saw a significant increase in net income and diluted EPS for the quarter, primarily due to a higher gross margin, decreased operating expenses, and a substantial reduction in acquired in-process research and development (IPR&D) charges compared to the prior year. Key strategic developments include the integration of the Novartis Animal Health acquisition, which contributed to revenue growth in the animal health segment, and ongoing pipeline advancements. However, the company faces ongoing challenges related to patent expirations and generic competition for key products like Cymbalta and Alimta, which are expected to materially impact future revenues. Despite these headwinds, Lilly's financial position remains solid, supported by robust cash generation from operations.

Eli Lilly and Company's (LLY) Form 10-Q filing for the quarter ended June 30, 2015, reveals a slight increase in revenue but a notable decrease in net income and earnings per share compared to the prior year's period. This decline in profitability was primarily driven by significant one-time charges, including those related to the acquisition of Novartis Animal Health (Novartis AH), acquired in-process research and development (IPR&D) expenses from new collaborations, asset impairment, restructuring charges, and a debt extinguishment loss. Despite these headwinds, the company generated positive operating cash flow and maintained a strong liquidity position. The company's revenue growth was modest, with increased volume in the U.S. and internationally, partly due to the inclusion of Novartis AH revenues. However, patent expirations for key drugs like Cymbalta and Evista continued to negatively impact sales. Management provided updated full-year 2015 financial guidance, expecting EPS in the range of $2.20 to $2.30 and revenue between $19.7 billion and $20.0 billion, reflecting confidence in the underlying business performance and new product launches.

Eli Lilly and Company (LLY) reported its first-quarter 2015 financial results, showing a slight 1% decrease in worldwide revenue to $4.64 billion. This decline was primarily attributed to unfavorable foreign exchange rates and the ongoing impact of patent expirations for key drugs like Cymbalta and Evista. However, these headwinds were largely offset by the inclusion of revenue from the recently acquired Novartis Animal Health business, higher U.S. pricing, and increased volumes for several other products. Net income saw a more significant decrease of 27% to $529.5 million, translating to $0.50 earnings per share (EPS), down from $0.68 in the prior year. This drop in profitability was influenced by substantial acquired in-process research and development (IPR&D) charges and increased asset impairment, restructuring, and other special charges, particularly related to the integration of Novartis Animal Health. Despite these challenges, the company reiterated its full-year EPS guidance and maintained its revenue expectations, signaling confidence in its ongoing operations and strategic initiatives.

Eli Lilly and Company reported a significant decline in revenue and net income for the third quarter and the first nine months of 2014 compared to the prior year. This downturn was primarily driven by the loss of U.S. patent exclusivity for key drugs like Cymbalta and Evista, which led to immediate generic competition and a sharp drop in sales for these products. Despite the revenue challenges, Lilly has made strategic moves, including the announced acquisition of Novartis Animal Health (NAH) and collaborations on promising late-stage pipeline assets such as baricitinib and tanezumab. The company also saw growth in several key product areas and international markets, partially offsetting the declines. Investors should monitor the impact of ongoing patent challenges for Alimta and the development of new drug candidates as key drivers for future growth and potential risks.

Eli Lilly and Company reported a significant revenue decline of 17% for both the second quarter and the first six months of 2014, primarily due to the loss of U.S. patent exclusivity for key drugs like Cymbalta and Evista. This revenue drop directly impacted net income, which fell by 39% in the quarter and 47% year-to-date. Despite these challenges, the company is actively managing its costs, with decreases noted in R&D and marketing, selling, and administrative expenses. Looking ahead, Lilly is pursuing strategic growth through its late-stage pipeline, which includes promising candidates in diabetes, oncology, and autoimmune diseases. The company also announced a major acquisition of Novartis Animal Health, signaling a commitment to expanding its animal health segment. While patent expirations are a near-term headwind, Lilly's diversified portfolio and ongoing pipeline development offer potential for future recovery and growth.

Eli Lilly and Company reported a significant decrease in revenue and net income for the first quarter of 2014 compared to the same period in 2013. This decline was primarily attributed to the loss of U.S. patent exclusivity for key products like Cymbalta and Evista, leading to the introduction of generic competition. Despite the revenue drop, the company saw some growth in international markets and from its animal health division. Management highlighted ongoing efforts to manage costs and a robust late-stage pipeline with several promising drug candidates in development. The company also announced a significant agreement to acquire Novartis Animal Health for approximately $5.4 billion, signaling a strategic expansion into the animal health sector. Financial expectations for the full year 2014 were updated to reflect these developments, with an expected EPS range of $2.70 to $2.78.

Eli Lilly and Company (LLY) reported solid revenue growth for the first nine months of 2013, with total revenue increasing by 4% to $17.3 billion. This growth was primarily driven by key products like Cymbalta, insulins, animal health products, Alimta, Cialis, and Trajenta. However, the company experienced a 9% decrease in net income for the third quarter of 2013, largely due to a significant one-time income recognized in the prior year related to the exenatide revenue-sharing obligation. For the nine-month period, net income increased by 21% to $3.96 billion. The company is facing upcoming patent expirations for key drugs like Cymbalta and Evista, which are expected to materially impact future results due to anticipated generic competition. Lilly is actively managing these upcoming patent cliffs through a new $5 billion share repurchase program and continued investment in its R&D pipeline.

Eli Lilly and Company's second quarter 2013 report shows solid revenue and net income growth, driven by key products like Cymbalta and Cialis, as well as an increase in collaboration and other revenues. Despite the ongoing impact of patent expirations for products like Zyprexa, the company demonstrated resilience with a 6% increase in worldwide revenue for the quarter, reaching $5.93 billion, and a 31% surge in net income to $1.21 billion. The company's financial health remains robust, supported by strong operational cash flow and a significant reduction in marketing, selling, and administrative expenses. However, investors should note the upcoming patent expiries for Cymbalta in the U.S. (December 2013) and Evista (March 2014), which are expected to lead to substantial revenue declines due to generic competition. Lilly is actively managing these challenges by focusing on growth in emerging markets, Japan, and its animal health business, alongside its patent-protected products.

Eli Lilly and Company reported flat revenue of $5.60 billion for the first quarter of 2013 compared to the prior year, with net income significantly increasing by 53% to $1.55 billion, translating to diluted earnings per share (EPS) of $1.42, up from $0.91 in Q1 2012. This substantial profit increase was largely driven by a one-time income of $495.4 million recognized from the transfer of exenatide commercial rights outside the U.S. to Amylin Pharmaceuticals. Despite the strong net income growth, the company faces significant headwinds from patent expirations, notably for Zyprexa, which caused substantial sales declines, and upcoming patent cliffs for Cymbalta and Evista. Lilly is actively managing these challenges by focusing on growth in patent-protected products, emerging markets, and its animal health business. The company maintained its full-year EPS guidance of $4.10 to $4.25 and revenue forecast of $22.6 billion to $23.4 billion, indicating confidence in its strategic initiatives and product pipeline.

Eli Lilly and Company reported mixed financial results for the quarter and nine months ended September 30, 2012. Total revenue saw a significant decline year-over-year, primarily due to the loss of patent exclusivity for Zyprexa. However, net income for the third quarter increased year-over-year, largely driven by a substantial one-time income recognized from the early payment of the Amylin revenue-sharing obligation. Despite the revenue headwinds from patent expirations, the company continues to invest in research and development for its future pipeline, with several promising candidates in late-stage clinical trials. While the loss of Zyprexa exclusivity presents a significant challenge, other key products like Cymbalta, Alimta, and Effient demonstrated growth, and the animal health business also showed positive performance. Investors should closely monitor the company's progress in its late-stage pipeline and its strategy to mitigate the impact of patent expiries on future revenue. The company also faces ongoing patent and product liability litigation, which could materially impact future results, although management believes it will not have a material adverse effect on the company's consolidated financial position or liquidity.

Eli Lilly and Company reported a decrease in revenue and net income for the second quarter and first six months of 2012 compared to the same periods in 2011. This decline was primarily driven by the loss of patent exclusivity for Zyprexa, which significantly impacted sales. Despite this, several key products like Cymbalta, Alimta, and the animal health portfolio showed growth, partially offsetting the overall revenue decline. Key financial metrics indicate a challenging period, with net income and EPS both decreasing. However, the company raised its full-year earnings per share guidance, signaling confidence in future performance. Lilly's R&D pipeline remains robust with numerous compounds in late-stage development, crucial for mitigating the impact of upcoming patent expirations. The company also continues to manage its financial position, with total debt decreasing and sufficient operating cash flow expected to cover operational needs, dividends, and share repurchases.

Eli Lilly and Company reported $5.60 billion in revenue for the first quarter of 2012, a decrease of 4% compared to the same period in 2011. This decline was primarily attributed to the loss of patent exclusivity for its drug Zyprexa, which significantly impacted sales. Despite the revenue dip, net income remained strong at $1.01 billion, though it was down 4% year-over-year, resulting in diluted earnings per share of $0.91. The company's strategic focus remains on growing its patent-protected products, expanding in emerging markets and Japan, and advancing its animal health business to offset patent expirations. Lilly also highlighted its robust late-stage pipeline with several new molecular entities in Phase III trials across various therapeutic areas. Operationally, research and development expenses increased slightly to $1.15 billion, supporting its ongoing drug development efforts. The company also addressed a significant increase in its effective tax rate to 24.3% from 17.1% in the prior year, partly due to the absence of certain tax benefits. Lilly maintained a strong liquidity position with $4.12 billion in cash and cash equivalents as of March 31, 2012, and reiterated its commitment to dividends and its ongoing share repurchase program, although no shares were repurchased in Q1 2012.

Eli Lilly and Company reported a revenue increase of 9% to $6.15 billion for the third quarter of 2011 and an 8% increase to $18.24 billion for the first nine months of the year. Despite the revenue growth, driven by key products like Cymbalta, animal health products, and Alimta, net income saw a decrease of 5% to $1.24 billion for the quarter and 11% to $3.49 billion for the nine-month period. This decline in profitability was attributed to lower gross margin percentage, increased marketing, selling, and administrative costs, and significant acquired in-process research and development (IPR&D) charges related to a diabetes collaboration. The company is navigating significant patent expirations and ongoing litigation, particularly with the upcoming loss of exclusivity for Zyprexa in major markets and ongoing challenges for Alimta and Strattera. Management is focused on mitigating these impacts through the growth of patent-protected products, emerging markets, and its animal health business. Financial conditions remain solid with substantial cash and equivalents, though the company is self-insured for product liability losses.

Eli Lilly and Company reported revenue growth for the second quarter and first six months of 2011, primarily driven by key products like Cymbalta, Zyprexa, and animal health offerings. However, net income and earnings per share saw a decline compared to the previous year, largely due to increased selling, general, and administrative costs, lower gross margins, and significant charges related to acquired in-process research and development (IPR&D) and restructuring initiatives. The company also highlighted the ongoing impact of U.S. healthcare reform, including a mandatory pharmaceutical manufacturers' fee. Looking ahead, Eli Lilly faces significant patent expirations for key products such as Zyprexa (expected in late 2011), which will likely lead to a rapid and severe decline in revenue for these drugs. The company is strategically focusing on growing its patent-protected products, expanding in emerging markets and Japan, and strengthening its animal health business to mitigate these upcoming challenges. Despite these headwinds, Eli Lilly reiterated its 2011 earnings per share guidance and expects sufficient cash flow from operations to fund its operational needs.

Eli Lilly and Company's (LLY) first quarter 2011 results show a decrease in net income and earnings per share compared to the prior year, primarily driven by increased investment in research and development, a significant charge for acquired in-process research and development related to a new diabetes collaboration, and restructuring costs. Despite a 6% increase in revenue driven by key products like Cymbalta and animal health, these factors led to a 15% drop in net income to $1.06 billion and a 16% decrease in EPS to $0.95. Investors should note the company's ongoing patent challenges and the looming loss of exclusivity for major products like Zyprexa, which is expected to significantly impact future revenues. However, Lilly continues to invest heavily in its pipeline, with over 65 potential new drugs in human testing, and is strategically pursuing collaborations to bolster its future growth. The company's financial position remains solid, with substantial cash and investments, and management is confident in its ability to fund operations and dividends.

Eli Lilly and Company's 10-Q filing for the period ending September 29, 2010, reveals a company navigating a complex operating environment with both successes and challenges. While the filing indicates progress in certain areas, investors should pay close attention to the interplay of revenue growth, product pipeline developments, and the impact of generic competition. The company's ability to effectively manage its research and development pipeline and defend its market share against upcoming patent expirations will be critical for sustained growth and profitability.

Eli Lilly and Company's (LLY) Form 10-Q/A filed on August 1, 2010, primarily serves as an amendment to correct an inadvertent filing error related to an Interactive Data File for the quarter ended June 30, 2010. The company is a large accelerated filer, indicating its significant market capitalization and regular filing history. This amendment does not alter the previously reported financial performance for the quarter but addresses a procedural issue with an exhibit. Investors should note that this filing is an amendment to correct a data file exhibit and does not introduce new financial information or materially change the previously reported results for the period ending June 30, 2010. The company confirms it has filed all required reports and is not a shell company. The outstanding common shares as of July 20, 2010, were approximately 1.15 billion.

Eli Lilly and Company's second quarter 2010 results, as reported in their 10-Q filing dated July 29, 2010, show a company navigating patent expirations while focusing on its pipeline. The company's financial performance during this period requires careful investor consideration, particularly regarding revenue trends and the impact of generic competition on key products. Management's discussion likely centers on strategies to mitigate these challenges and capitalize on future growth opportunities from new drug approvals. Investors should pay close attention to the specific revenue figures for flagship products and the progress of their research and development efforts. The filing will provide insights into Lilly's financial health, liquidity, and any significant legal or regulatory matters that could influence future performance. Understanding these elements is crucial for assessing the company's ability to sustain profitability and deliver shareholder value in the evolving pharmaceutical landscape.

Eli Lilly and Company's (LLY) 10-Q filing for the period ending March 30, 2010, indicates a company navigating a dynamic pharmaceutical landscape. While specific financial figures are not detailed in the provided excerpt, the filing structure suggests a comprehensive review of the company's performance and operational status. Investors should pay close attention to the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for insights into revenue drivers, cost management, and any significant operational changes during the quarter. The inclusion of 'Legal Proceedings' and 'Risk Factors' also signals potential challenges or uncertainties that could impact future performance and shareholder value.

Eli Lilly and Company (LLY) reported its financial results for the period ending September 29, 2009, in its 10-Q filing. The company's performance reflects the ongoing challenges and opportunities within the pharmaceutical industry during this period. Investors should pay close attention to revenue drivers, product pipeline developments, and any significant legal or regulatory matters that could impact future profitability and growth. The filing provides a snapshot of the company's financial health and operational performance during the third quarter of 2009, offering insights into its ability to navigate market dynamics and maintain its competitive position.